Diabetes Remission Possible Through Structured Interventions

Experts say early, weight-focused treatment and close monitoring are key to achieving lasting diabetes remission.

Published on Feb. 18, 2026

Got story updates? Submit your updates here. ›

Current research shows that remission of type 2 diabetes is increasingly achievable through structured interventions, particularly those focused on substantial weight loss. Experts emphasize the importance of deploying modern tools like GLP-1 receptor agonists, SGLT2 inhibitors, and digital coaching in a progressive, evidence-based manner to address the underlying metabolic dysfunction, rather than just suppressing glucose levels. They highlight that the greatest opportunity for remission is through early interventions in recently diagnosed patients.

Why it matters

Achieving diabetes remission is crucial, as it can prevent long-term complications and improve overall health outcomes. However, the path to remission requires a structured, multifaceted approach that goes beyond simply managing glucose levels. Understanding the key factors and best practices for driving remission can help healthcare providers deliver more effective, personalized care for patients with type 2 diabetes.

The details

Experts say that for diabetes remission to be considered, glycemic markers must return to the non-diabetic range without the continued use of glucose-lowering medications, sustained over time. This is typically defined as an HbA1c below 6.5% maintained for at least 3 months. Other markers like fasting glucose and continuous glucose monitoring can also be used. The majority of clinicians now start newly diagnosed patients on metformin and a GLP-1 receptor agonist, while also immediately implementing an intensive lifestyle intervention and digital coaching program. If lifestyle management alone is not enough, metabolic surgery can be a reliable option for durable remission, especially for patients with a BMI over 35. Successful remission trajectories are characterized by early, aggressive metabolic intervention, regular touchpoints with a clinical team, use of continuous glucose monitoring to shape behavior, and a consistent reduction in visceral fat.

  • The 2023 study published in Diabetes Care showed remission rates at 1 year.
  • The September 2025 systematic review and meta-analysis in Diabetes Care pooled 18 nonsurgical randomized controlled trials.
  • The DiRECT trial, a primary care-led weight management program for diabetes, focused on intensive lifestyle intervention.

The players

William Hsu, MD

Chief medical officer of L-Nutra, a longevity science company that offers diabetes remission solutions, and the former vice president of Harvard's Joslin Diabetes Center.

Eve Elizabeth Pennie, MD

An epidemiologist with the Texas Department of State Health Services in Austin, Texas.

Got photos? Submit your photos here. ›

What they’re saying

“Clinically, diabetes remission is defined as the return of glycemic markers to the nondiabetic range without the continued use of glucose-lowering medications, sustained over time.”

— William Hsu, MD, Chief medical officer of L-Nutra (Medscape)

“Diabetes remission indicates sustained normoglycemia with minimal use of pharmacologic agents; however, underlying cardiometabolic risks persist, and continued surveillance for complications will occur.”

— Eve Elizabeth Pennie, MD, Epidemiologist, Texas Department of State Health Services (Medscape)

“The greatest opportunity for achieving diabetes remission is through early, weight-centered interventions.”

— Eve Elizabeth Pennie, MD, Epidemiologist, Texas Department of State Health Services (Medscape)

“The so-called 'standard care' focuses on returning biomarkers to below a specific level at the cost of polypharmacy and patient burden. The reality is when you stop these meds, glucose goes back up.”

— William Hsu, MD, Chief medical officer of L-Nutra (Medscape)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.